View in EDS

LILRB2 blockade facilitates macrophage repolarization and enhances T cell-mediated antitumor immunity.

Saved in:
Bibliographic Details
Title: LILRB2 blockade facilitates macrophage repolarization and enhances T cell-mediated antitumor immunity.
Authors: Jones DC; ICC, Early Oncology R&D, AstraZeneca, Cambridge, UK desjones@hotmail.com.; Immunocore Ltd, Abingdon, UK., Irving L; Biologics Engineering, AstraZeneca, Cambridge, UK., Dudley R; ICC, Early Oncology R&D, AstraZeneca, Cambridge, UK., Blümli S; Biologics Engineering, AstraZeneca, Cambridge, UK., Wolny M; Biologics Engineering, AstraZeneca, Cambridge, UK., Chatzopoulou EI; ICC, Early Oncology R&D, AstraZeneca, Cambridge, UK., Pryts S; ICC, Early Oncology R&D, AstraZeneca, Gaithersburg, Maryland, USA., Ahuja S; Dynamic Omics, CGR, Discovery Sciences, R&D, AstraZeneca, Gaithersburg, Maryland, USA., Rees DG; Biologics Engineering, AstraZeneca, Cambridge, UK., Sandercock AM; Biologics Engineering, AstraZeneca, Cambridge, UK., Rajan S; Biologics Engineering, AstraZeneca, Gaithersburg, Maryland, USA., Varkey R; Biologics Engineering, AstraZeneca, Gaithersburg, Maryland, USA., Kierny M; Biologics Engineering, AstraZeneca, Gaithersburg, Maryland, USA., Kayserian A; Biologics Engineering, AstraZeneca, Gaithersburg, Maryland, USA., Mulgrew K; ICC, Early Oncology R&D, AstraZeneca, Gaithersburg, Maryland, USA., Bowyer G; ICC, Early Oncology R&D, AstraZeneca, Cambridge, UK., Songvilay S; ICC, Early Oncology R&D, AstraZeneca, Cambridge, UK., Bienkowska K; ICC, Early Oncology R&D, AstraZeneca, Cambridge, UK., Glover MS; Dynamic Omics, CGR, Discovery Sciences, R&D, AstraZeneca, Gaithersburg, Maryland, USA., Hess S; Dynamic Omics, CGR, Discovery Sciences, R&D, AstraZeneca, Gaithersburg, Maryland, USA., Dovedi SJ; ICC, Early Oncology R&D, AstraZeneca, Cambridge, UK., Wilkinson RW; ICC, Early Oncology R&D, AstraZeneca, Cambridge, UK.; Immunocore Ltd, Abingdon, UK., Arnaldez F; Early Oncology R&D, AstraZeneca, Gaithersburg, Maryland, USA., Cobbold M; ICC, Early Oncology R&D, AstraZeneca, Gaithersburg, Maryland, USA.
Source: Journal for immunotherapy of cancer [J Immunother Cancer] 2025 Apr 17; Vol. 13 (4). Date of Electronic Publication: 2025 Apr 17.
Publication Type: Journal Article
Journal Info: Publisher: BMJ Publishing Group Ltd Country of Publication: England NLM ID: 101620585 Publication Model: Electronic Cited Medium: Internet ISSN: 2051-1426 (Electronic) Linking ISSN: 20511426 NLM ISO Abbreviation: J Immunother Cancer Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 40246582
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: LILRB2 blockade facilitates macrophage repolarization and enhances T cell-mediated antitumor immunity.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Jones+DC%22">Jones DC</searchLink>; ICC, Early Oncology R&D, AstraZeneca, Cambridge, UK desjones@hotmail.com.; Immunocore Ltd, Abingdon, UK.<br /><searchLink fieldCode="AU" term="%22Irving+L%22">Irving L</searchLink>; Biologics Engineering, AstraZeneca, Cambridge, UK.<br /><searchLink fieldCode="AU" term="%22Dudley+R%22">Dudley R</searchLink>; ICC, Early Oncology R&D, AstraZeneca, Cambridge, UK.<br /><searchLink fieldCode="AU" term="%22Blümli+S%22">Blümli S</searchLink>; Biologics Engineering, AstraZeneca, Cambridge, UK.<br /><searchLink fieldCode="AU" term="%22Wolny+M%22">Wolny M</searchLink>; Biologics Engineering, AstraZeneca, Cambridge, UK.<br /><searchLink fieldCode="AU" term="%22Chatzopoulou+EI%22">Chatzopoulou EI</searchLink>; ICC, Early Oncology R&D, AstraZeneca, Cambridge, UK.<br /><searchLink fieldCode="AU" term="%22Pryts+S%22">Pryts S</searchLink>; ICC, Early Oncology R&D, AstraZeneca, Gaithersburg, Maryland, USA.<br /><searchLink fieldCode="AU" term="%22Ahuja+S%22">Ahuja S</searchLink>; Dynamic Omics, CGR, Discovery Sciences, R&D, AstraZeneca, Gaithersburg, Maryland, USA.<br /><searchLink fieldCode="AU" term="%22Rees+DG%22">Rees DG</searchLink>; Biologics Engineering, AstraZeneca, Cambridge, UK.<br /><searchLink fieldCode="AU" term="%22Sandercock+AM%22">Sandercock AM</searchLink>; Biologics Engineering, AstraZeneca, Cambridge, UK.<br /><searchLink fieldCode="AU" term="%22Rajan+S%22">Rajan S</searchLink>; Biologics Engineering, AstraZeneca, Gaithersburg, Maryland, USA.<br /><searchLink fieldCode="AU" term="%22Varkey+R%22">Varkey R</searchLink>; Biologics Engineering, AstraZeneca, Gaithersburg, Maryland, USA.<br /><searchLink fieldCode="AU" term="%22Kierny+M%22">Kierny M</searchLink>; Biologics Engineering, AstraZeneca, Gaithersburg, Maryland, USA.<br /><searchLink fieldCode="AU" term="%22Kayserian+A%22">Kayserian A</searchLink>; Biologics Engineering, AstraZeneca, Gaithersburg, Maryland, USA.<br /><searchLink fieldCode="AU" term="%22Mulgrew+K%22">Mulgrew K</searchLink>; ICC, Early Oncology R&D, AstraZeneca, Gaithersburg, Maryland, USA.<br /><searchLink fieldCode="AU" term="%22Bowyer+G%22">Bowyer G</searchLink>; ICC, Early Oncology R&D, AstraZeneca, Cambridge, UK.<br /><searchLink fieldCode="AU" term="%22Songvilay+S%22">Songvilay S</searchLink>; ICC, Early Oncology R&D, AstraZeneca, Cambridge, UK.<br /><searchLink fieldCode="AU" term="%22Bienkowska+K%22">Bienkowska K</searchLink>; ICC, Early Oncology R&D, AstraZeneca, Cambridge, UK.<br /><searchLink fieldCode="AU" term="%22Glover+MS%22">Glover MS</searchLink>; Dynamic Omics, CGR, Discovery Sciences, R&D, AstraZeneca, Gaithersburg, Maryland, USA.<br /><searchLink fieldCode="AU" term="%22Hess+S%22">Hess S</searchLink>; Dynamic Omics, CGR, Discovery Sciences, R&D, AstraZeneca, Gaithersburg, Maryland, USA.<br /><searchLink fieldCode="AU" term="%22Dovedi+SJ%22">Dovedi SJ</searchLink>; ICC, Early Oncology R&D, AstraZeneca, Cambridge, UK.<br /><searchLink fieldCode="AU" term="%22Wilkinson+RW%22">Wilkinson RW</searchLink>; ICC, Early Oncology R&D, AstraZeneca, Cambridge, UK.; Immunocore Ltd, Abingdon, UK.<br /><searchLink fieldCode="AU" term="%22Arnaldez+F%22">Arnaldez F</searchLink>; Early Oncology R&D, AstraZeneca, Gaithersburg, Maryland, USA.<br /><searchLink fieldCode="AU" term="%22Cobbold+M%22">Cobbold M</searchLink>; ICC, Early Oncology R&D, AstraZeneca, Gaithersburg, Maryland, USA.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101620585%22">Journal for immunotherapy of cancer</searchLink> [J Immunother Cancer] 2025 Apr 17; Vol. 13 (4). <i>Date of Electronic Publication: </i>2025 Apr 17.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22BMJ+Publishing+Group+Ltd%22">BMJ Publishing Group Ltd </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>101620585 <i>Publication Model: </i>Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>2051-1426 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2220511426%22">20511426 </searchLink><i>NLM ISO Abbreviation: </i>J Immunother Cancer <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=40246582
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1136/jitc-2024-010012
    Languages:
      – Code: eng
        Text: English
    Titles:
      – TitleFull: LILRB2 blockade facilitates macrophage repolarization and enhances T cell-mediated antitumor immunity.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Jones DC
      – PersonEntity:
          Name:
            NameFull: Irving L
      – PersonEntity:
          Name:
            NameFull: Dudley R
      – PersonEntity:
          Name:
            NameFull: Blümli S
      – PersonEntity:
          Name:
            NameFull: Wolny M
      – PersonEntity:
          Name:
            NameFull: Chatzopoulou EI
      – PersonEntity:
          Name:
            NameFull: Pryts S
      – PersonEntity:
          Name:
            NameFull: Ahuja S
      – PersonEntity:
          Name:
            NameFull: Rees DG
      – PersonEntity:
          Name:
            NameFull: Sandercock AM
      – PersonEntity:
          Name:
            NameFull: Rajan S
      – PersonEntity:
          Name:
            NameFull: Varkey R
      – PersonEntity:
          Name:
            NameFull: Kierny M
      – PersonEntity:
          Name:
            NameFull: Kayserian A
      – PersonEntity:
          Name:
            NameFull: Mulgrew K
      – PersonEntity:
          Name:
            NameFull: Bowyer G
      – PersonEntity:
          Name:
            NameFull: Songvilay S
      – PersonEntity:
          Name:
            NameFull: Bienkowska K
      – PersonEntity:
          Name:
            NameFull: Glover MS
      – PersonEntity:
          Name:
            NameFull: Hess S
      – PersonEntity:
          Name:
            NameFull: Dovedi SJ
      – PersonEntity:
          Name:
            NameFull: Wilkinson RW
      – PersonEntity:
          Name:
            NameFull: Arnaldez F
      – PersonEntity:
          Name:
            NameFull: Cobbold M
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 17
              M: 04
              Text: 2025 Apr 17
              Type: published
              Y: 2025
          Identifiers:
            – Type: issn-electronic
              Value: 2051-1426
          Numbering:
            – Type: volume
              Value: 13
            – Type: issue
              Value: 4
          Titles:
            – TitleFull: Journal for immunotherapy of cancer
              Type: main
ResultId 1